Strategic Financial Concepts LLC acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) in Q4 CY2024, but sales rose 10.6% year on year to $172 ...

Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

周三，BTIG分析师Mark Massaro调整了Neogenomics（NASDAQ: NEO）的股票目标价，从此前的18.00美元下调至17.00美元，同时维持对该股的买入评级。根据 InvestingPro 数据显示，该股目前交易价格为12.70美元，过去一周股价大幅下跌10%。此次调整是在上月公司宣布首席执行官兼重组专家Chris ...

周三，Morgan ...

NeoGenomics (NASDAQ:NEO – Get Free Report) had its price objective decreased by analysts at Needham & Company LLC from $19.00 to $18.00 in a report released on Wednesday,Benzinga reports.

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 10.6% year on year to $172 million. On the other hand, ...

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall ...

NEOGENOMICS ($NEO) posted quarterly earnings results on Tuesday, February 18th. The company reported earnings of $0.04 per share, beating estimates of $0.03 by $0.01 ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to look for. NeoGenomics met analysts’ revenue expectations last quarter ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 10.6% year on year to $172 million. On the other hand, the company ...